HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer

AAD PROPOSING SUNSCREEN TFM's SPF RATINGS BE SHIFTED UPWARDS

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

AAD PROPOSING SUNSCREEN TFM's SPF RATINGS BE SHIFTED UPWARDS to "encourage people to use the higher levels of sun protection products," the American Academy of Dermatology said in March 18 comments on the sunscreen tentative final monograph. The TFM designates products with SPF 2 to 4 as "minimal; SPF 4 to 8, "moderate"; SPF 8 to 12, "high"; SPF 12 to 20, "very high"; and SPF 20 to 30, "ultra." AAD believes that the ratings "need to be shifted upwards, i.e., 'minimal' (SPF 4-8), 'moderate' (SPF 8-12), etc." SPF 15 products, recommended by many dermatologists for "good protection regardless of skin type," AAD said, should not be designated "high" or "very high," but rather "should be labeled as nothing more than 'good.'"

Table

View full table

Topics

Tags:
Consumer
Latest Headlines

‘Cowboy Companies’ To Be Named, Shamed And Fined Under EU Supply Chain Directive

Beauty Firms Should Draft AI Use Policies, Even If They Don’t Plan To Use AI – Attorney

Supreme Court To Hear RICO Complaint Against CBD Firms As Hemp Regulation Remains AWOL

Nestlé Joins Forces With Dr Reddy’s In India To Grow Dietary Supplements Reach

See All
UsernamePublicRestriction

Register

RS000349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By